Veritas Pharma Inc.: CANNEVERT Presses on th its Goal of Clinical Trials
(firmenpresse) - CANNEVERT PRESSES ON TO ITS GOAL OF CLINICAL TRIALS
May 8, 2017, Vancouver, B.C. - Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that its research arm, Cannevert Therapeutics Ltd. is moving swiftly towards properly certified and scientifically rigorous clinical trials of a cultivar of significant interest in area of cannabis research.
There are many claims for the usefulness of cannabis in treating various disease conditions. However, many of these trials would not meet the approval of regulatory agencies and thus it is important that Cannevert performs trials of the highest standard that meet regulatory standards. This is important in the case where the material administered is not a single chemical but rather a mixture. Cannevert is working under the hypothesis that synergy exists between the different chemical constituents found in cannabis cultivars. Attempts to mimic this by using the pure cannabinoid molecules has yet to be associated with notably improved therapeutic actions as demonstrated by clinical trials conducted under the surveillance of government regulatory bodies. The use of sufficient and varied animal models enables the Cannevert to ascertain more clearly, and in a defined manner, the true therapeutic potential of cannabis cultivars. With respect to pain and emesis, Cannevert is actively pursuing this clinical route of conducting human experiments to the highest level possible. Obviously, achieving this level is not easy or simple, yet the amount evidence that Cannevert has accrued in this area is thought to be sufficient to persuade regulatory agencies. In view of the increasing workload, and continuing with the goal of implementing clinical trials this year, Cannevert has this month increased its laboratory staff by 25%.
From Dr. Lui Franciosis (Veritas CEO) recent attendance of The Planet Microcap Showcase 2017 in Las Vegas, he concluded that despite the many broad claims as to therapeutic utility of relatively undefined cannabis sources, these remain unsubstantiated by good scientific evidence. Cannevert under Veritas is truly committed to establishing the soundest experimental and clinical evidence to justify the use of specific cannabis strains for the treatment of specific diseases. Thus, taking cannabis out of the realm of therapeutic fancies into the realm of scientifically established and medical reality. Dr. Franciosi went on to say, This research work takes time to conduct, but the knowledge and understanding achieved are worth the wait, both to society and investors. Canneverts President, Professor Michael Walker stated, I am very impressed by the quality of the scientific evidence being produced by our team, and I imagine that it will lead to substantial clinical evidence, beyond that currently available.
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTLs unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The companys commercial mission is to patent protect CTLs IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.
Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: www.veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
"Dr. Lui Franciosi"
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir(at)veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.
Leseranfragen:
Datum: 08.05.2017 - 18:53 Uhr
Sprache: Deutsch
News-ID 540973
Anzahl Zeichen: 4995
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 287 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Veritas Pharma Inc.: CANNEVERT Presses on th its Goal of Clinical Trials
"
steht unter der journalistisch-redaktionellen Verantwortung von
Veritas Pharma Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
